摘要
为了比较多西他赛单药每周与3周疗法治疗老年晚期非小细胞肺癌的效果,每周疗法组(A组)于d1、d8和d15给予多西他赛35mg/m2溶于100mL生理盐水静脉滴入,每4周为1个周期;3周疗法组(B组)于d1给予多西他赛75mg/m2溶于100mL生理盐水静脉滴入,每21d为1个周期。每2个周期评价疗效,筛选有效者继续化疗,6个周期后分析有效率、累积毒性、生活质量评分等。结果A、B组的有效率分别为25.0%和21.7%、中位疾病进展时间(TTP)分别为4.41和3.96个月,中位生存期分别为10.50和9.17个月。上述两组指标比较P均>0.05,差异无统计学意义。A组较B组的血液学毒性和脱发不良反应轻,生活质量有明显改善。初步研究结果提示,在不减低疗效的同时多西他赛单周疗法较3周疗法的血液学毒性低,且生活质量有明显改善。
The objective of this study was compare the efficacy of docetaxel monotherapy in senile advanced non small cell lung cancer by weekly and 3-weekly.Weekly therapy group （Group A） were adminstred docetaxel 35 mg/m2 solutioned by 100 mL saline on d1,d8,d15,and 4 weeks as one cycle;3-weekly therapy group （Group B） were adminitred docetaxel 75 mg/m2 on d1,and 3 weeks as one cycle.The efficacy was assessed every two cycles and keep on chemotheray for those who get good outcome.After 6 cycles the efficacy,accumulated toxicity and life quality scores were assessed.The efficacy,the median time to progress and median survival time were 25.0% and 21.7%,4.41 and 3.96 months,10.50 and 9.17 months respectivly.The values of P were all above 0.05,and the difference had no statis significency.Comparing to Group B,Group A had a mild hematoxicity and hairless,the life quality got significent approved.The prime study outcome indicated that the docetaxel mono weekly therapy has a milder hematoxcity and a better life quality without affecting efficacy than 3-weekly therapy.
出处
《中华肿瘤防治杂志》
CAS
2010年第16期1311-1312,共2页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺
多西他赛
药物疗法
carcinoma
non-small-cell lung
docetaxel
drug therpy
